Table 3.
Peptide Sequence | Secondary Structure | hRXRα-LBD | hRXRα-LBD:GRIP-1 | hRXRα-LBD:9cRA | hRXRα-LBD:9cRA: GRIP-1 |
---|---|---|---|---|---|
G219SHMTSSANEDMPVERILE237 | H1 | 73% | −5 | −3 | −5 |
A241VEPKTET248 | H1 | 100% | −1 | 0 | 1 |
A241VEPKTETYVE251 | H1 | 100% | −8 | −3 | −11 |
A271ADKQLFT278 | H3 | 99% | −14 | −15 | −30 |
A271ADKQLFTL279 | H3 | 100% | −9 | −28 | −39 |
L279VEWAKRIPHFSELPLDDQ297 | H3 | 30% | −2 | −1 | −2 |
L301RAGWNEL308 | H4 | 37% | −11 | −12 | −20 |
L309IASFSHRSIAVKDGIL325 | H5 | 57% | −5 | −24 | −27 |
L326ATGLHVHRNSAHSAGVGAIF346 | Beta | 65% | −5 | −9 | −12 |
D347RVLTEL353 | H7 | 48% | −5 | −31 | −35 |
V354SKMRDMQM362 | H7 | 69% | −8 | −31 | −38 |
D363KTEL367 | H8 | 41% | −8 | −6 | −6 |
D363KTELGCL370 | H8 | 20% | −4 | 0 | −1 |
R371AIVLFNPDSKGLSNPAEVEA391 | H8 | 50% | −4 | 1 | −3 |
I373VLFNPDSKGLSNPAEVEA391 | H8 | 53% | −4 | 0 | −5 |
L392REKVYASL400 | H9 | 3% | −1 | −1 | 0 |
E401AYCKHKYPEQPGRF415 | H9 | 40% | −2 | 1 | −2 |
L419LRLPALRSIGLKC432 | H10 | 86% | −6 | −37 | −47 |
L419LRLPALRSIGLKCLEHLFF438 | H10 | 91% | −9 | −26 | −37 |
P423ALRSIGLKCLEHLFF438 | H11 | 88% | −8 | −25 | −37 |
L433EHLFF438 | H11 | 80% | −8 | −1 | −10 |
F439KLIGDTPIDTFL451 | H11 | 88% | −1 | −3 | −5 |
F450LMEM454 | H12 | 92% | −17 | 4 | −14 |
L455EAPHQMT462 | CTERM | 84% | −3 | −2 | −6 |
Values reflect differences in percent deuterium incorporation for each peptic peptide averaged across five time points (15 s, 30 s, 120 s, 900 s, 3600 s) relative to apo-hRXRα-LBD (column 3). Negative values indicate an increased level of protection for that peptide under the indicated conditions and are color coded in increasing shades of blue. Differences <5% are considered insignificant (shown in grey). Peptides are listed from N- to C- terminus, holo structural element indicated in column 2. Observed hRXRα-LBD amino acid contacts with 9cRA are in red. Observed hRXRα-LBD amino acid contacts with GRIP1 are underlined.